{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-21-000009","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.456620+00:00","generated_at":"2026-06-29T12:53:39.745885+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace Q2 revenue $12.6M (+65% YoY); initial implants up 100%; reaffirms FY guidance","bullets":["Total revenue $12.6M (+65% YoY); initial implant revenue $9.2M (+100% YoY, +14% QoQ).","Net loss $8.5M vs $8.8M; cash $127.9M; long-term debt $49.4M.","Reaffirmed FY2021 guidance: total revenue ~$47M, initial implant ~$36M.","Received up to $9.3M NIH BRAIN grant to evaluate RNS System for Lennox-Gastaut Syndrome.","Plans to start enrolling adolescent epilepsy patients before year-end; IDE for primary generalized epilepsy in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-21-000009","json":"https://secwatch.observer/filing/0001528287-21-000009.json","markdown":"https://secwatch.observer/filing/0001528287-21-000009.md","text":"https://secwatch.observer/filing/0001528287-21-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828721000009/0001528287-21-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828721000009/npce-20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:53:39.745885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}